These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36779549)

  • 21. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
    Raynaud JP; Gardette J; Rollet J; Legros JJ
    BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
    Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
    BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
    Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testosterone Therapy: What We Have Learned From Trials.
    Corona G; Torres LO; Maggi M
    J Sex Med; 2020 Mar; 17(3):447-460. PubMed ID: 31928918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
    Lundy SD; Parekh NV; Shoskes DA
    J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Rhoden EL; Morgentaler A
    Int J Impot Res; 2006; 18(2):201-5. PubMed ID: 16177827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
    Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
    JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
    Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
    Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
    Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study.
    Legros JJ; Meuleman EJ; Elbers JM; Geurts TB; Kaspers MJ; Bouloux PM;
    Eur J Endocrinol; 2009 May; 160(5):821-31. PubMed ID: 19211706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testosterone replacement therapy (TRT) and prostate cancer: An updated systematic review with a focus on previous or active localized prostate cancer.
    Lenfant L; Leon P; Cancel-Tassin G; Audouin M; Staerman F; Rouprêt M; Cussenot O
    Urol Oncol; 2020 Aug; 38(8):661-670. PubMed ID: 32409202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testosterone and depression: systematic review and meta-analysis.
    Zarrouf FA; Artz S; Griffith J; Sirbu C; Kommor M
    J Psychiatr Pract; 2009 Jul; 15(4):289-305. PubMed ID: 19625884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update in testosterone therapy for men.
    Corona G; Rastrelli G; Forti G; Maggi M
    J Sex Med; 2011 Mar; 8(3):639-54; quiz 655. PubMed ID: 21711483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A small-scale clinical trial to determine the safety and efficacy of testosterone replacement therapy in hypogonadal men with spinal cord injury.
    Bauman WA; Cirnigliaro CM; La Fountaine MF; Jensen AM; Wecht JM; Kirshblum SC; Spungen AM
    Horm Metab Res; 2011 Jul; 43(8):574-9. PubMed ID: 21717386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 12-month observation of testosterone replacement effectiveness in a general population of men.
    Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
    Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lean tissue mass and energy expenditure are retained in hypogonadal men with spinal cord injury after discontinuation of testosterone replacement therapy.
    Bauman WA; La Fountaine MF; Cirnigliaro CM; Kirshblum SC; Spungen AM
    J Spinal Cord Med; 2015 Jan; 38(1):38-47. PubMed ID: 24968251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.